In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the international multicenter Liberty Asthma VOYAGE trial supported approval of dupilumab for the treatment of moderate-to-severe asthma in this age group by the Food and Drug Administration in October.
